TOPOTECAN FOR CERVICAL CANCER
Topotecan for the treatment of recurrent and stage IVB carcinoma of the cervix
Background: This project is being undertaken as part of NICE’s single technology appraisal (STA) process. The STA process is specifically designed for the appraisal of a single product, device or other technology, with a single indication. The STA process normally covers new technologies and is designed to provide recommendations in the form of NICE guidance soon after the technology is introduced into the UK market. The principal evidence in the STA process is submitted by the manufacturer or sponsor of the technology.
CRD in collaboration with CHE will review the evidence submission and prepare an Evidence Review Group (ERG) report.
Conducted by: CRD and the Centre of Health Economics, University of York
Commissioned by: NIHR HTA Programme on behalf of NICE
Current status: Completed 2009
Further details:
Project page on the NIHR HTA Programme website
Related guidance:
Commissioned to inform NICE guidance: Topotecan for the treatment of recurrent carcinoma of the cervix. London: National Institute for Clinical Excellence; 2009.
